Biotechnological companies using AI
Generate Biomedicines (NASDAQ: GENB), an artificial intelligence--focused drug development company, successfully completed its public stock offering on February 26, 2026, collecting $400 million by selling shares at $16 each. The company began trading on the Nasdaq exchange on February 27, 2026, under the symbol GENB.